Prostate cancer is the third most common cancer in the world. Diosynth Biotechnology has been awarded by Dendreon with a long –term contract to supply its novel vaccine for prostate cancer in anticipation of the USFDA approval.
The novel vaccine Provenge (sipuleucel-T) once approved will be the first cancer vaccine to reach the market. The product is currently in late-stage clinical development and is also now undergoing a biologics license application (BLA) with the FDA.
Once approved, Diosynth will manufacture Provenge for market launch and commercial sale in its facility in
According to Richard Basile, vice president, global marketing & sales of Diosynth Biotechnology, they are expecting to receive FDA approval in time to begin making Provenge for commercial purposes in the beginning of year 2007.
Source: The Pharma Technologist
Comment Preview